Shaanxi Micot Pharma Enrolls First Patient in Acute Ischemic Stroke Drug Trial
Shaanxi Micot Pharmaceutical Technology (HKG:2335) enrolled the first patient in a phase Ib/II clinical trial of MT1002. The drug is being tested for the treatment of acute ischemic stroke, according to a Friday Hong Kong bourse filing.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.